Survival and risk analysis of patients with COVID-19 in Iran

Abstract

Objective: To evaluate the risk factors of death caused by COVID-19 in Iran. Methods: This study was a retrospective cohort study from February 20, 2020, to August 22, 2022, in the hospitals in Isfahan, Iran. The data were collected through a researcher-made checklist. To determine the risk factors of the death, logistic regression and Cox regression models were used. For each variable, the odds ratio and 95% confidence interval were also reported. Results: 1 885 Patients were included. The age of deceased persons was significantly higher than that of the surviving persons. The risk of death for the age group above 60 years was about 14 times higher than that of people aged 19-35 years [95%CI: 14.41 (2.02-102.99), P<0.01]. Hypertension [95%CI: 1.92 (1.47-2.5), P<0.01], diabetes [95%CI: 1.62 (1.23-2.13), P<0.001], and chronic obstructive pulmonary disease [95%CI: 1.92 (1.47-2.50), P<0.01] were also risk factors of mortality. Conclusions: This study reveals that the mortality rate due to COVID-19 is associated with old age, longer hospitalization in the ICU, increased length of stay, and comorbidities of high blood pressure, diabetes, and chronic pulmonary disease.

Keywords

Cause / Death / Survival / COVID-19 / Risk factors / Iran

References

[1] Hao YJ, Wang YL, Wang MY, Zhou L, Shi JY, Cao JM, et al. The origins of COVID—19 pandemic: A brief overview. Transbound Emerg Dis 2022; 69(6): 3181-3197.

[2] CDC Museum COVID—19 Timeline. [Online] Available from: https://www.cdc.gov/museum/timeline/covid19.html [Accessed on February 15, 2024].

[3] COVID—19 Coronavirus pandemic 2023. [Online] Available from: https://www.worldometers.info/coronavirus/ [Accessed on February 15, 2024].

[4] Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation period of COVID—19 caused by unique SARS—CoV—2 strains: A systematic review and meta—analysis. JAMA Network Open 2022; 5(8): e2228008-e.

[5] Chen Z, Peng Y, Wu X, Pang B, Yang F, Zheng W, et al. Comorbidities and complications of COVID—19 associated with disease severity, progression and mortality in China with centralized isolation and hospitalization: A systematic review and meta—analysis. Front Public Health 2022; 10: 923485.

[6] Fathi M, Vakili K, Sayehmiri F, Mohamadkhani A, Hajiesmaeili M, Rezaei—Tavirani M, et al. The prognostic value of comorbidity for the severity of COVID—19: A systematic review and meta—analysis study. PLoS One 2021; 16(2): e0246190.

[7] Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID—19. Nature Med 2023; 29(2): 334-343.

[8] Jalili M, Payandemehr P, Saghaei A, Sari HN, Safikhani H, Kolivand P. Characteristics and mortality of hospitalized patients with COVID—19 in Iran: A national retrospective cohort study. Ann Intern Med 2021; 174(1): 125-127.

[9] Namayandeh SM, Dehghan H, Lotfi MH, Khajehaminian MR, Hosseini S, Bahrevar V, et al. Clinical courses of 24,563 hospitalized COVID—19 patients during the first 12 months of the pandemic in the Central City of Iran. Sci Rep 2023; 13(1): 6521.

[10] Diop M, Ba PS, Cisse VM, Lakhe NA, Fall B, Lo M, et al. Risk factors for COVID—19 related death during the first three waves of the pandemic in an epidemic treatment center at Dakar, Senegal. Adv Infect Dis 2023; 13(2): 117-131.

[11] Ali MM, Malik MR, Ahmed AY, Bashir AM, Mohamed A, Abdi A, et al. Survival analysis of all critically ill patients with COVID—19 admitted to the main hospital in Mogadishu, Somalia, 30 March — 12 June 2020: Which interventions are proving effective in fragile states? Int J Infect Dis 2022; 114: 202-209.

[12] Pontes L, Danski MT, Piubello SM, Pereira JF, Jantsch LB, Costa LB, et al. Clinical profile and factors associated with the death of COVID—19 patients in the first months of the pandemic. Escola Anna Nery 2021; 26: e20210203.

[13] Garbin JR, Leite FM, Lopes—Júnior LC, Dell’Antonio CS, Dell’Antonio LS, Santos AP. Analysis of survival of patients hospitalized with COVID—19 in Espírito Santo, Brazil. Int J Environ Res Public Health 2022; 19(14): 8709.

[14] Muyinda A, Ingabire PM, Nakireka S, Tumuhaise C, Namulema E, Bongomin F, et al. Survival analysis of patients with COVID—19 admitted at six hospitals in Uganda in 2021: A cohort study. Arch Public Health 2022; 80(1): 233.

[15] Setianegari Y, Kurniaty L, Luhulima DE, Utomo BS, Langi LA, Arodes ES, et al. Factors associated with death and ICU referral among COVID—19 patients hospitalized in secondary referral academic hospital in East Jakarta, Indonesia. J Clin Virol Plus 2022; 2(2): 100068.

[16] Adham D, Habibzadeh S, Ghobadi H, Jajin SA, Abbasi—Ghahramanloo A, Moradi—Asl E. Epidemiological characteristics and mortality risk factors among COVID—19 patients in Ardabil, Northwest of Iran. BMC Emerg Med 2021; 21(1): 1-6.

[17] Mirjalili M, Dehghani M, Raadabadi M, Dehghani A. Death risk among COVID—19 patients in Yazd, Iran: A hospital—based case—cohort study. J Milit Med 2021; 23(3): 274-282.

[18] Najafi N, Bakhshi P, Alizadeh—Navaei R, Ahangarkani F, Akbari Z, Mirzakhani M, et al. Clinical epidemiology of deceased COVID—19 patients in Mazandaran heart center, 2020—2021. J Mazandaran Univ Med Sci 2022; 32(207): 79-89.

[19] Najjar A, Daei MM, Dodangeh S. Prediction of the risk factors for COVID—19 infection in progression to severe disease in Bu—Ali Sina Hospital, Qazvin, Iran. Pathobiol Res 2021; 24(1): 55-61.

[20] Tian R, Wu W, Wang C, Pang H, Zhang Z, Xu H, et al. Clinical characteristics and survival analysis in critical and non—critical patients with COVID—19 in Wuhan, China: A single—center retrospective case control study. Sci Rep 2020; 10(1): 17524.

[21] Hergens MP, Bell M, Haglund P, Sundström J, Lampa E, Nederby—Öhd J, et al. Risk factors for COVID—19—related death, hospitalization and intensive care: A population—wide study of all inhabitants in Stockholm. Eur J Epidemiol 2022; 37(2): 157-165.

[22] Salinas—Escudero G, Carrillo—Vega MF, Granados—García V, Martínez—Valverde S, Toledano—Toledano F, Garduño—Espinosa J. A survival analysis of COVID—19 in the Mexican population. BMC Public Health 2020; 20(1): 1-8.

[23] Sania A, Mahmud AS, Alschuler DM, Urmi T, Chowdhury S, Lee S, et al. Risk factors for COVID—19 mortality among telehealth patients in Bangladesh: A prospective cohort study. PLoS Global Public Health 2023; 3(6): e0001971.

[24] Wu R, Ai S, Cai J, Zhang S, Qian ZM, Zhang Y, et al. Predictive model and risk factors for case fatality of COVID—19: A cohort of 21,392 cases in Hubei, China. Innovation 2020; 1(2): 100022.

[25] Cantero—Quintero S, Sáez—Martínez M, Castellanos—Garrido AB. Risk factors for severity and mortality in adults testing positive for COVID—19 in the VI Health Area of Albacete. Enfermería Clín 2022; 32(4): 217-224.

[26] Soto A, Quiñones—Laveriano DM, Azañero J, Chumpitaz R, Claros J, Salazar L, et al. Mortality and associated risk factor in patients hospitalized due to COVID—19 in a Peruvian reference hospital. PLoS One 2022; 17(3): e0264789.

[27] Rafati S, Teamur Aghamol T, Bahrampour A, Khorrami F, Kheirandish M, Khosravi B, et al. Survival analysis of COVID—19 patients in an Iranian population. Dis Diagn 2022; 12(1): 12-20.

[28] Ghelmani SY, Salehabadi HS, Moazen H, Nazmiah H, Tafti TF, Kabirzadeh A, et al. Evaluation of risk factors related to life status of patients with COVID—19 hospitalized in Yazd. J Tolooebehdasht 2022. DOI: 10.18502/tbj.v21i2.10343.

[29] Cueto—Manzano AM, Espinel—Bermúdez MC, Hernández—González SO, Rojas—Campos E, Nava—Zavala AH, Fuentes—Orozco C, et al. Risk factors for mortality of adult patients with COVID—19 hospitalised in an emerging country: A cohort study. BMJ Open 2021; 11(7): e050321.

[30] Ahmadi A, Ardeshiri S, Nezhadi VR, Pajoohesh A, Moghadam TN, Sabaghan M, et al. Risk factors for mortality in hospitalized patients with COVID—19: A cross—sectional study in southwestern Iran. Iranian Red Crescent Med J 2021. Corpus ID: 261812364.

[31] Salehi M, Mohammadi MT, Abtahi SH, Ghazi SF, Sobati A, Bozorgmehr R, et al. Risk factors of death in mechanically ventilated COVID—19 patients: A retrospective multi—center study. 2022. Preprint. DOI: https://doi.org/10.21203/rs.3.rs-1362678/v1.